Corpus overview


Overview

MeSH Disease

Human Phenotype

Hypertension (64)

Fever (16)

Obesity (16)

Cough (14)

Dyspnea (10)


Transmission

Seroprevalence
    displaying 41 - 50 records in total 64
    records per page




    Clinical symptoms, comorbidities and complications features in severe and non-severe patients with COVID-19: a systematic review and meta-analysis without cases duplication

    Authors: Zhufeng Wang; Hongsheng Deng; Changxing Ou; Jingyi Liang; Yingzhi Wang; Mei Jiang; Shiyue Li

    doi:10.21203/rs.3.rs-30787/v1 Date: 2020-05-21 Source: ResearchSquare

    Background: The pandemic of COVID-19 posed a challenge to global healthcare. The mortality rates of severe cases range from 8.1% to 31.8%, and it is particularly important to identify risk factors that aggravate the disease.Methods: We performed a systematic review of the literature with meta-analysis, using 7 databases to assess clinical characteristics, comorbidities and complications in severe and non-severe patients with COVID-19. All the observational studies were included. We performed a random or fixed effects model meta-analysis to calculate the pooled proportion and 95% CI. Measure of heterogeneity was estimated by Cochran’s Q statistic, I2 index and P value.Results: 4881 cases from 25 studies related to COVID-19 were included. The most prevalent comorbidity was hypertension HP hypertension MESHD (severe: 33.4%, 95% CI: 25.4% - 41.4%; non-severe 21.6%, 95% CI: 9.9% - 33.3%), followed by diabetes MESHD (severe: 14.4%, 95% CI: 11.5% - 17.3%; non-severe: 8.5%, 95% CI: 6.1% - 11.0%). The prevalence SERO of ARDS, AKI and shock HP were all higher in severe cases, with 41.1% (95% CI: 14.1% - 68.2%), 16.4% (95% CI: 3.4% - 29.5%) and 19.9% (95% CI: 5.5% - 34.4%), rather than 3.0% (95% CI: 0.6% - 5.5%), 2.2% (95% CI: 0.1% - 4.2%) and 4.1% (95% CI -4.8% - 13.1%) in non-severe patients, respectively. The death rate was higher in severe cases (30.3%, 95% CI: 13.8% - 46.8%) than non-severe cases (1.5%, 95% CI: 0.1% - 2.8%).Conclusions: Hypertension HP Hypertension MESHD, diabetes MESHD and cardiovascular diseases MESHD may be risk factors for COVID-19 patients to develop into severe cases.

    Number of International Arrivals Predicts Severity of the first Global Wave of the COVID-19 Pandemic

    Authors: Tiberiu A Pana; Sohinee Bhattacharya; David T Gamble; Zahra Pasdar; Weronika A Szlachetka; Jesus A Perdomo-Lampignano; David McLernon; Phyo K Myint

    doi:10.1101/2020.05.13.20100677 Date: 2020-05-16 Source: medRxiv

    Importance: Reported death MESHD rates from different countries during the COVID-19 pandemic vary. Lack of universal testing and death underreporting make between-country comparisons difficult. The country-level determinants of COVID-19 mortality are unknown. Objective: Derive a measure of COVID-related death rates that is comparable across countries and identify its country-level predictors. Design: An ecological study design of publicly available data was employed. Countries reporting >25 COVID-related deaths until 08/06/2020 were included. The outcome was log mean mortality rate from COVID-19, an estimate of the country-level daily increase in reported deaths MESHD during the ascending phase of the epidemic curve. Potential determinants assessed were most recently published demographic parameters (population and population density, percentage population living in urban areas, median age TRANS, average body mass index, smoking prevalence SERO), Economic parameters (Gross Domestic Product per capita); environmental parameters: pollution levels, mean temperature (January-April)), co-morbidities ( prevalence SERO of diabetes MESHD, hypertension HP hypertension MESHD and cancer MESHD), health system parameters (WHO Health Index and hospital beds per 10,000 population); international arrivals and the stringency index, as a measure of country-level response to COVID-19. Multivariable linear regression was used to analyse the data. Results: Thirty-seven countries were included. Of all country-level predictors included in the multivariable model, only total number of international arrivals was significantly associated with the mean death rate: Beta 0.040 (95% Confidence Interval 0.017, 0.063), P <0.001. Conclusions and Relevance: International travel TRANS was directly associated with the mortality slope and thus potentially the spread of COVID-19. Very early restrictions on international travel TRANS may be a very effective strategy to control COVID outbreak and prevent related deaths.

    Identifying baseline clinical features of people with COVID-19

    Authors: Daniela Ferreira-Santos; Priscila Maranhao; Matilde Monteiro-Soares

    doi:10.1101/2020.05.13.20100271 Date: 2020-05-16 Source: medRxiv

    Objectives: To describe baseline clinical characteristics of adult TRANS patients with COVID-19. Methods: We conducted a scoping review of the evidence available at LitCovid, until March 23th, 2020, and selected articles that reported the prevalence SERO of socio-demographic characteristics, symptoms and co-morbidities in adults TRANS with COVID-19. Results: In total, 1 572 publications were published on LitCovid. We have included 56 articles in our analysis, with 89% conducted in China, and 75% contained inpatients. Three studies were conducted in North America and one in Europe. Participants age TRANS ranged from 28 to 70 years, with balanced gender TRANS distribution. Proportion of asymptomatic TRANS cases were from 2 to 79%. The most common reported symptoms were fever HP fever MESHD [4-99%], cough HP [4-92%], dyspnoea/shortness of breath MESHD [1-90%], fatigue HP fatigue MESHD 4-89%], myalgia HP myalgia MESHD [3-65%], and pharyngalgia [2-61%], while regarding co-morbidities we found cardiovascular disease MESHD [1-40%], hypertension HP hypertension MESHD [0-40%] and cerebrovascular disease MESHD [1-40%]. Such heterogeneity impairs the conduction of meta-analysis. Conclusions: The infection by COVID-19 seems to affect people in a very diverse manner and with different characteristics. With the available data it is not possible to clearly identify those at higher risk of being infected with this condition. Furthermore, the evidence from countries other than China is, at the day, too scarce.

    Clinical features of 162 fatal cases of COVID-19: a multi-center, retrospective study

    Authors: Xianlong Zhou; Guoyong Ding; Qing Fang; Jun Guo; Luyu Yang; Ping Wang; Shouzhi Fu; Ang Li; Jian Xia; Jiangtao Yu; Jianyou Xia; Min Ma; Zhuanzhuan Hu; Lei Huang; Ruining Liu; Cheng Jiang; Shaoping Li; Mingxia Yu; Xizhu Xu; Yan Zhao; Quan Hu; Weijia Xing; Zhigang Zhao

    doi:10.21203/rs.3.rs-29357/v1 Date: 2020-05-15 Source: ResearchSquare

    Understanding the epidemiological and clinical characteristics of fatal cases infected with SARS-CoV-2 is import to develop appropriate preventable intervention programs in hospitals. Demographic data, clinical symptoms, clinical course, co-morbidities, laboratory findings, CT scans, treatments and complications of 162 fatal cases were retrieved from electric medical records in 5 hospitals of Wuhan, China. The median age TRANS was 69.5 years old (IQR: 63.0-77.25; range: 29-96). 112 (69.1%) cases were men. Hypertension HP Hypertension MESHD (45.1%) was the most common co-morbidity, but 59 (36.4%) cases had no co-morbidity. At admission, 131 (81.9%) cases were assessed as severe or critical. However, 39 (18.1%) were assessed as moderate. Moderate cases had a higher prevalence SERO of hypertension HP hypertension MESHD and chronic lung disease HP lung disease MESHD comparing with severe or critical cases (P<0.05, respectively). 126 (77.8%) and 132 (81.5%) cases received antiviral treatment and glucocorticoids, respectively. 116 (71.6%) cases were admitted to ICU and 137 (85.1%) cases received mechanical ventilation. Respiratory failure HP Respiratory failure MESHD or acute respiratory distress syndrome MESHD respiratory distress HP syndrome (93.2%) was the most common complication. The young cases of COVID-19, without co-morbidity and in a moderate condition at admission could develop fatal outcome. We need to be more cautious in case management of COVID-19 for preventing the fatal outcomes.

    Comparison of clinical characteristics and risk factors in hospitalized patients with SARS-CoV-2, MERS-CoV, and SARS-CoV infection MESHD

    Authors: Zhengtu Li; Xidong Wang; Guansheng Su; Zeguang Zheng; Shaoqiang Li; Yuwei Ye; Qiuxue Deng; Jinchuang Li; Xiaoyu Xiong; Xinguang Wei; Zeqiang Lin; Zichen Jie; Feng Ye

    doi:10.21203/rs.3.rs-28847/v1 Date: 2020-05-14 Source: ResearchSquare

    Herein, we compared the risk factors, clinical presentation of patients hospitalized with SARS-CoV-2, SARS-CoV MESHD, or MERS-CoV infection MESHD. Our data sources include PubMed, Embase, CNKI, and Ovid/Medline. The proportion of male TRANS patients with COVID-19 was higher than who with SARS but lower than who with MERS (p<0.001). More patients with COVID-19 had coexisting chronic medical conditions than those with SARS (p<0.001) but fewer than those with MERS (p<0.001), and the prevalence SERO of hypertension HP hypertension MESHD (17%) and smoking history (14%) was higher than in patients with SARS (p<0.001). Furthermore, the symptom of fever HP fever MESHD (53%), hemoptysis HP (1%), diarrhea HP diarrhea MESHD (4%) and vomiting HP vomiting MESHD (3%) of COVID-19 were significantly lower than that in patients with SARS or MERS. The level of ALT and AST in COVID-19 was significantly lower (p<0.001), however, thrombocytopenia HP thrombocytopenia MESHD, high LDH were common. Summary, male TRANS, smoking history and hypertension HP hypertension MESHD were the most common risk factors for hospitalization with COVID-19; and the clinical feature was less severe in COVID-19.

    Early estimation of the risk factors for hospitalisation and mortality by COVID-19 in Mexico

    Authors: Maria Fernanda Carrillo-Vega; Guillermo Salinas-Escudero; Carmen Garcia-Peña; Luis Miguel Gutierrez-Robledo; Lorena Parra-Rodriguez

    doi:10.1101/2020.05.11.20098145 Date: 2020-05-14 Source: medRxiv

    Background. With its high prevalence SERO of chronic non-degenerative diseases, it is suspected that in Mexico there is a high risk of fatal complications from COVID-19. The present study aims to estimate the risk factors for hospitalisation and death MESHD in the Mexican population infected by SARS-CoV-2. Methods and Findings. We used the publicly available data released by the Epidemiological Surveillance System for Viral Respiratory Diseases MESHD of the Mexican Ministry of Health ( Secretaria de Salud MESHD, SS). All records of positive SARS-CoV-2 cases were included. Two multiple logistic regression models were fitted to estimate the association between the hospitalisation and mortality, with other covariables. Data on 10,544 individuals (57.68% men), with mean age TRANS 46.47 SD 15.62, were analysed. Men were about 1.54 times as likely to be hospitalized than women (p<0.001, 95% C.I. 1.37-1.74); individuals aged TRANS 50-74 and >=74 years were more likely to be hospitalized than people from 25-49 years (OR 2.05, p<0.001, 95% C.I. 1.81-2.32, and OR 23.84, p<0.001, 95% C.I. 2.90-5.15, respectively). People with hypertension HP hypertension MESHD, obesity HP obesity MESHD, and diabetes MESHD were more likely to be hospitalised than people without these morbidities (p<0.01). Men had more risk of death MESHD in comparison to women (OR=1.53, p<0.001, 95% C.I. 1.30-1.81) and individuals aged TRANS 50-74 and [≥]75 years were more likely to die than people from 25-49 years (OR 1.96, p<0.001, 95% C.I. 1.63-2.34, and OR 3.74, p<0.001, 95% C.I. 2.80-4.98, respectively). Hypertension HP Hypertension MESHD, obesity HP obesity MESHD, and diabetes MESHD presented in combination, provided a higher risk of dying in comparison to not having these diseases (OR=2.10; p<0.001, 95% C.I. 1.50-2.93). Hospitalisation, intubation and pneumonia HP pneumonia MESHD conferred a higher risk of dying (OR 5.02, p<0.001, 95% C.I. 3.88-6.50; OR 4.27, p<0.001, 95% C.I. 3.26-5.59, and OR=2.57; p<0.001, 95% C.I. 2.11-3.13, respectively). The main limitation of our study is the lack of information on mild ( asymptomatic TRANS) or moderate cases of COVID-19. Conclusions. The present study points out that in Mexico, where an important proportion of the population develops two or more chronic conditions simultaneously, high mortality is a sever outcome for those infected by SARS-CoV-2.

    Effects of pre-existing morbidities on occurrence of death MESHD among COVID-19 disease patients: A systematic review and meta-analysis

    Authors: Mostaured Khan; Md Nuruzzaman Khan; Md. Golam Mustagir; Juwel Rana; Md Saiful Islam; Md Iqbal Kabir

    doi:10.1101/2020.05.08.20095968 Date: 2020-05-13 Source: medRxiv

    Abstract Background: Coronavirus disease 2019 (COVID-19), the most hectic pandemic of the era, is increasing exponentially and taking thousands of lives worldwide. This study aimed to assess the prevalence SERO of pre-existing morbidities among COVID-19 infected MESHD patients and their mortality risks against each type of pre-existing morbidity category. Methods: To conduct this systematic review and meta-analysis, Medline, Web of Science, Scopus, and CINAHL databases were searched using specified relavent keywords. Further searches were conducted using the reference list of the selected studies, renowned pre-print servers (e.g., medRxiv, bioRixv, SSRN), and relevant journal websites. Studies written in the English language included if those were conducted among COVID-19 patients with and without comorbidities and presented survivor vs. non-survivor counts or hazard/odds of deaths or survivors against types of pre-existing morbidities. Comorbidities reported in the selected studies were grouped into eight categories. The pooled likelihoods of deaths in each category were estimated using a fixed or random-effect model, based on the heterogeneity assessment. Publication bias was assessed by visual inspection of the funnel plot asymmetry and Eggers regression test. Trim and Fill method was used if there any publication bias was found. Results: A total of 42 studies included in this study comprised of 39,398 samples. The most common pre-existing morbidities in COVID-19 infected MESHD patients were hypertension HP hypertension MESHD (36.5%), cardiovascular disease MESHD (11.9%), and diabetes MESHD (22.0%). The higher likelihood of deaths was found among COVID-19 patients who had pre-existing cardiovascular diseases MESHD (OR: 3.32, 95% CI: 2.79-3.95), immune and metabolic disorders MESHD (OR: 2.39, 95% CI: 2.00-2.85), respiratory diseases MESHD (OR: 2.02, 95% CI: 1.80-2.26), cerebrovascular diseases MESHD (OR: 4.12, 95% CI: 3.04-5.58), any types of cancers MESHD (OR: 2.22, 95% CI: 1.63-3.03), renal (OR: 3.02, 95% CI: 2.60-3.52), and liver diseases MESHD (OR: 1.44, 95% CI: 1.21-1.71). Conclusions: This study provides evidence of a higher likelihood of deaths among COVID-19 patients against morbidity categories. These findings could potentially help healthcare providers to sort out the most endangered COVID-19 patients by comorbidities, take precautionary measures during hospitalization, assess susceptibility to death, and prioritize their treatment, which could potentially reduce the number of fatalities in COVID-19.

    Characteristics of SARS-CoV-2 positive and complicated COVID-19 patient cohorts in Israel: A comparative analysis

    Authors: Chen Yanover; Barak Mizrahi; Nir Kalkstein; Karni Marcus; Pinchas Akiva; Yael Barer; Varda Shalev; Gabriel Chodick

    doi:10.1101/2020.05.07.20091652 Date: 2020-05-11 Source: medRxiv

    Reliably identifying patients at increased risk for COVID-19 complications could guide clinical decisions, public health policies, and preparedness efforts. To date, the most globally accepted definitions of at-risk patients rely, primarily, on epidemiological characterization of hospitalized COVID-19 patients. However, such characterization overlooks, and fails to correct for, the prevalence SERO of existing conditions in the wider SARS-CoV-2 positive population. Here, we analyze the complete medical records of all SARS-CoV-2 infected MESHD individuals (N=4,353) in a large Israeli health organization (representing a population of 2.3 million people), of whom 173 experienced moderate or severe symptoms of COVID-19, to identify the conditions that increase the risk of disease complications, in various age TRANS and sex strata. Our analysis suggests that cardiovascular and kidney diseases MESHD, obesity HP obesity MESHD, and hypertension HP hypertension MESHD are significant risk factors for COVID-19 complications, as previously reported. Interestingly, it also indicates that depression MESHD (e.g., odds ratio, OR, for males TRANS 65 years or older: 2.94, 95% confidence intervals [1.55, 5.58]; P-value = 0.014) as well cognitive and neurological disorder MESHD (e.g., OR for individuals [≥] 65 year old: 2.65 [1.69, 4.17]; P-value < 0.001) are significant risk factors; and that smoking and background of respiratory diseases MESHD do not significantly increase the risk of complications. Adjusting existing risk definitions following these observations may improve their accuracy and impact the global pandemic containment efforts.

    Severe obesity HP obesity MESHD is associated with higher in-hospital mortality in a cohort of patientswith COVID-19 in the Bronx, New York

    Authors: Leonidas Palaiodimos; Damianos G. Kokkinidis; Weijia Li; Dimitrios Karamanis; Jennifer Ognibene; Shitij Arora; William N. Southern; Christos S. Mantzoros

    doi:10.1101/2020.05.05.20091983 Date: 2020-05-09 Source: medRxiv

    Background & Aims: New York is the current epicenter of Coronavirus disease MESHD 2019 (COVID-19) pandemic. The underrepresented minorities, where the prevalence SERO of obesity HP obesity MESHD is higher, appear to be affected disproportionately. Our objectives were to assess the characteristics and early outcomes of patients hospitalized with COVID-19 in the Bronx and investigate whether obesity HP obesity MESHD is associated with worse outcomes. Methods: This retrospective study included the first 200 patients admitted to a tertiary medical center with COVID-19. The electronic medical records were reviewed at least three weeks after admission. The primary endpoint was in-hospital mortality. Results: 200 patients were included ( female TRANS sex: 102, African American: 102). The median BMI was 30 kg/m2. The median age TRANS was 64 years. Hypertension HP Hypertension MESHD (76%), hyperlipemia MESHD (46.2%), and diabetes MESHD (39.5%) were the three most common comorbidities. Fever HP Fever MESHD (86%), cough HP (76.5%), and dyspnea HP dyspnea MESHD (68%) were the three most common symptoms. 24% died during hospitalization (BMI <25 kg/m2: 31.6%, BMI 25-34 kg/m2: 17.2%, BMI[≥]35 kg/m2: 34.8%, p= 0.03). The multivariate analysis for mortality, demonstrates that BMI[≥]35 kg/m2 (OR: 3.78; 95% CI: 1.45 - 9.83; p=0.006), male TRANS sex (OR: 2.74; 95% CI: 1.25 - 5.98; p=0.011) and increasing age TRANS (OR: 1.73; 95% CI: 1.13 - 2.63; p=0.011) were independently associated with higher inhospital mortality. Similar results were obtained for the outcomes of increasing oxygen requirement and intubation. Conclusions: In this cohort of hospitalized patients with COVID-19 in a minority-predominant population, severe obesity HP obesity MESHD, increasing age TRANS, and male TRANS sex were associated with higher in-hospital mortality and in general worse in-hospital outcomes.

    PREEXISTING COMORBIDITIES PREDICTING SEVERE COVID-19 IN OLDER ADULTS TRANS IN THE UK BIOBANK COMMUNITY COHORT

    Authors: Janice L Atkins; Jane AH Masoli; Joao Delgado; Luke C Pilling; Chia-Ling C Kuo; George Kuchel; David Melzer

    doi:10.1101/2020.05.06.20092700 Date: 2020-05-08 Source: medRxiv

    Background: Older COVID-19 hospitalized patients frequently have hypertension HP hypertension MESHD, diabetes MESHD or coronary heart disease MESHD ( CHD MESHD), but whether these are more common than in the population is unclear. During the initial epidemic in England, virus testing for older adults TRANS was restricted to symptomatic hospitalized patients. We aimed to estimate associations between pre-existing diagnoses and COVID-19 status, in a large community cohort. Methods: UK Biobank (England) participants assessed 2006 to 2010, followed in hospital discharge records to 2017. Demographic and pre-existing common diagnoses association tested with COVID-19 status (16th March to 14th April 2020) in logistic models, adjusted for demographics, study site and other diagnoses. Results: There were 274,356 participants aged TRANS 65+, including 448 (0.16%) hospitalized COVID-19 patients. Common co-morbidities in patients were hypertension HP hypertension MESHD (58.5%), coronary heart disease MESHD ( CHD MESHD, 21.1%), history of fall HP or fragility fractures MESHD (30.6%), and type 2 diabetes MESHD (19.6%). However, in adjusted models, COVID-19 patients were more likely than other participants to have pre-existing dementia HP dementia MESHD (OR=3.07 95% CI 1.71 to 5.50), COPD MESHD (OR= 1.82 CI 1.33 to 2.49), depression MESHD (OR=1.81 CI 1.36 to 2.40), type 2 diabetes MESHD (OR=1.70 CI 1.30 to 2.21), chronic kidney disease HP chronic kidney disease MESHD and atrial fibrillation HP atrial fibrillation MESHD. Hypertension HP Hypertension MESHD was modestly associated (OR=1.29 CI 1.04 to 1.59), but CHD MESHD (OR=0.92 CI 0.71 to 1.20) prevalence SERO was similar in COVID-19 patients and other participants. Conclusion: Specific co-morbidities are disproportionally common in older adults TRANS who develop severe COVID-19. Tailored interventions may be needed, as these results do not support simple age TRANS-based targeting to prevent severe COVID-19 infection MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.